Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.58 |
| ▸ | MAOA | P21397 | 11/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5625330 | 1.00 | CALML3 (0.58) | CALML3MAOACYP2C19CYP2C9MAOB | |
| SCHEMBL6925097 | 1.00 | CALML3 (0.58) | CALML3MAOACYP2C19CYP2C9MAOB | |
| Trifluoroacetic Acid SCHEMBL5623895 | 0.95 | CALML3 (0.54) | CALML3MAOACYP2C19CYP2C9MAOB | |
| SCHEMBL4016280 | 0.91 | CALML3 (0.47) | CALML3MAOA | |
| SCHEMBL7256130 | 0.91 | CALML3 (0.47) | CALML3MAOA | |
| SCHEMBL5233293 | 0.89 | CALML3 (0.48) | CALML3MAOACYP2C19CYP2C9MAOB | |
| SCHEMBL5833839 | 0.89 | CALML3 (0.48) | CALML3MAOACYP2C19CYP2C9MAOB | |
| SCHEMBL7256142 | 0.88 | CALML3 (0.45) | CALML3MAOACYP3A4 | |
| SCHEMBL6827066 | 0.88 | MAOA (0.64) | CALML3MAOAMAOB | |
| SCHEMBL6827071 | 0.88 | MAOA (0.64) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | claimed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| EP-1286998-B1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6638955-B2 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-10-28 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | CALML3 4326/4885MAOA 2239/4885CYP2C19 36/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | CALML3 4410/4885MAOA 652/4885CYP2C19 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.